NEW YORK (GenomeWeb) – The US Centers for Medicare & Medicaid Services has released the final national coverage determination for next-generation sequencing cancer panels, but most commercial payors have been fairly quiet about what they think about the policy and if they'll follow suit.
Commercial Payors Unlikely to Follow CMS Policy on NGS Cancer Panels in Short Term, Survey Suggests
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.